Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional) 

This Notice of Funding Opportunity (NOFO) invites Center Core (P30) applications for the National Institute on Aging’s (NIA) Artificial Intelligence and Technology Collaboratories (AITC) program. The AITC program promotes the development and implementation of artificial intelligence (AI) approaches and technology through research projects for aging and Alzheimer’s Disease (AD) and AD-related dementias (ADRD) research. All applications should propose strategies for addressing challenges surrounding AI and technology development and implementation, and to employ, when possible, best practices established in the fields of aging and AD/ADRD.

[Posted 9/10/25. Expires 10/16/25.]

Artificial Intelligence and Technology Collaboratory Coordinating Center (U24 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) invites Cooperative Agreement (U24) applications for the National Institute on Aging’s (NIA) Artificial Intelligence and Technology Collaboratory (AITC) Coordinating Center (AITCC). The AITC program promotes the development and implementation of artificial intelligence approaches and technology through research projects for aging and Alzheimer’s Disease (AD) and AD-related dementias (ADRD) research. The central functions of the AITCC are to (1) serve as a hub for the AITC program and facilitate and coordinate activities across the AITC program, (2) centralize and lead key stakeholder engagement activities across the AITC program, and (3) enhance the scientific impact and reach of the AITC program by actively disseminating information about the program and attracting new researchers from across the country to participate in program activities and resources.

[Posted 9/10/25. Expires 10/21/25.]

Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)

The purpose of this NOFO is to support and facilitate multidisciplinary research approaches for the development or improvement of technologies – including drugs, devices, products, or clinical practices – designed to improve fertility outcomes in patients dealing with infertility, particularly in the context of assisted reproductive technologies (ART).  This NOFO aims to position innovative and validated technologies for future clinical development.

[Posted 9/23/25. Expires 11/21/25.]

Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)

The Claude D. Pepper Older Americans Independence Center (OAIC) program’s goal is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on, and sustain progress in, a key area of aging research related to the mission of the OAIC program.

[Posted 9/10/25. Expires 10/21/25.]

NIH Blueprint for Neuroscience: Coordination Center for Interoception Research (BPCCIR) (U24, Clinical Trial Not Allowed)

This NOFO aims to foster interactions within the broad community of interoception researchers rather than focusing on disease-specific subdisciplines. Proposed efforts should: 1) establish and maintain a multidisciplinary team of interoception researchers to oversee and guide NBCCIR activities; 2) create and support digital communication platforms to facilitate networking, collaborations, and information dissemination; 3) plan, organize, and host at least one scientific meeting per year that will include NIH-funded interoception researchers, trainees, and other stakeholders; 4) identify challenges and future technological and scientific opportunities for the field of interoception and develop common terminology, data standards, and common data elements; and 5) generate metrics of success and plans to ensure the sustainability of the interoception research community. [Posted 9/2/2025. Due 11/10/2025.]

Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)

This notice of funding opportunity (NOFO) invites applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D)in vitromicrophysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organismin vivo. This NOFO is primarily focused on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids). However, systems developed using cells of nonhuman mammalian origin are acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified. Supported projects will be expected to advance the adoption of MPS in aging biology research and as new human-relevant tools for drug discovery. This NOFO uses the R21 activity code, which is intended for exploratory research at the early and conceptual stages of project development. Preliminary data are not required. An essential feature of responsive applications is the adoption of a multidisciplinary approach that includes expertise in aging biology and from disciplines such as stem cell biology, tissue and organ physiology, microfluidics, bioengineering, computational biology, pharmacology, and biostatistics. [Posted 8/26/2025. Application due date: 10/20/2025.]

NIH Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required)

PA-25-307: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans (per NOT-OD-18-212, “prospective basic science studies involving human participants”). [Posted 12/18/2024. Next due date for new applications is 10/16/2025.]

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required)

The purpose of the Stephen I. Katz Early Stage Investigator Research Project Grant is to provide a new pathway for Early Stage Investigators (ESIs) who wish to propose research projects in a new direction for which preliminary data do not exist. This notice of funding opportunity (NOFO) is open to a broad range of scientific research relevant to the mission of the participating NIH Institutes and Centers (ICs).
[Posted August 25, 2025. Expires August 26, 2028.]

Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)

Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) This Notice of Funding Opportunity is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications (ELSI) of genomics. [Posted 12/16/2024. Expires 2/27/2027]

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. [Posted 1/8/2025. Expires 1/8/2028]